| HOME >> BIOLOGY >> TECHNOLOGY |
Non-GAAP net income was $3.8 million, or $0.09 per diluted share, compared to a net loss of $5.3 million, or ($0.17) per diluted share, in the fourth quarter of 2007. On a GAAP basis, the Company reported net income of $1.1 million compared to a net loss of $6.6 million in the fourth quarter of 2007.
Full Year 2008 Financial Results
Revenue in the fiscal year 2008 increased to $114.9 million from $31.0 million in 2007, reflecting approximately $65.7 million in revenue from Sunstone, which was acquired in February of 2008. Revenue from distribution increased 57% to $43.7 million from $27.9 million in the year 2007, reflecting the acquisition of Rongheng in July 2008 and the sales growth of Wanwei's major products. Revenue from licensed products increased to $5.4 million from $3.1 million in 2007, reflecting sales and marketing efforts of Propess, Anpo, Ferriprox and Galake compared to the prior year.
Gross profit increased to $57.3 million from $4.3 million in 2007, and gross margin for the year was 49.9%, compared with 13.8% in 2007. The higher margin was largely due to revenue from the sales of the Company's branded OTC products, which yielded a gross margin of 77.2% in 2008.
Non-GAAP operating income reached $10.5 million in 2008 compared to a loss
of $8.9 million in the prior year, primarily reflecting the significant
increase in revenues contributed from acquired businesses in the year over
year period. Operating expenses of $17.4 million reflect increased advertising
and marketing, employee benefits, selling expenses and the amortization of
intangibles resulting from the acquisition of Sunstone. On a GAAP basis, the
Company's operating income improved significantly year over year to $3.7
million compared with an opera
'/>"/>
| SOURCE BMP Sunstone Corporation Copyright©2009 PR Newswire. All rights reserved |